Monetary values: Common Case Study
Jump to navigation
Jump to search
- The text on this page is taken from an equivalent page of the IEHIAS-project.
| Health End-Point | Low | Central | High | Unit (2010) per case |
|---|---|---|---|---|
| Sleep disturbance | 480 | 1,240 | 1,570 | Euro/year |
| Hypertension | 880 | 950 | 1,110 | Euro/year |
| Acute myocardial infarction | 4,675 | 86,200 | 436,200 | Euro |
| Increased mortality risk (infants) | 1,120,000 | 4,485,731 | 11,200,000 | Euro |
| New cases of chronic bronchitis | 43,000 | 66,000 | 100,000 | Euro |
| Severe COPD | 70,000 | 120,000 | 260,000 | Euro |
| Increased mortality risk - Value Of Life Years | 89,715 | 89,715 | 89,715 | Euro |
| Increased mortality risk - VSLacute | 1,121,433 | 1,121,433 | 5,607,164 | Euro |
| Increased mortality risk - VPFacute | 1,120,000 | 1,650,000 | 5,600,000 | Euro |
| Life expectancy reduction - Value of Life Years chronic | 37,500 | 59,810 | 213,820 | Euro |
| Respiratory hospital admissions | 2,990 | 2,990 | 8,074 | Euro |
| Cardiac hospital admissions | 2,990 | 2,990 | 8,074 | Euro |
| Work loss days (WLD) | 441 | 441 | 441 | Euro |
| Restricted activity days (RADs) | 194 | 194 | 194 | Euro |
| Minor restricted activity days (MRAD) | 57 | 57 | 57 | Euro |
| Lower respiratory symptoms | 57 | 57 | 57 | Euro |
| LRS excluding cough | 57 | 57 | 57 | Euro |
| Cough days | 57 | 57 | 57 | Euro |
| Medication use / bronchodilator use | 74 | 80 | 96 | Euro |
| Lung cancer | 69,080 | 719,212 | 4,187,879 | Euro |
| Leukaemia | 2,045,493 | 3,974,358 | 7,114,370 | Euro |
| Neuro-development disorders | 4,486 | 14,952 | 32,895 | Euro |
| Skin cancer | 10,953 | 13,906 | 26,765 | Euro |
| Osteoporosis | 2,990 | 5,682 | 8,074 | Euro |
| Renal dysfunction | 22,788 | 30,406 | 40,977 | Euro |
| Anaemia | 748 | 748 | 748 | Euro |